Detalles de la búsqueda
1.
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
Oncologist
; 27(11): 903-e834, 2022 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36181763
2.
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
Target Oncol
; 19(3): 411-421, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38467958
3.
Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients.
J Cancer Res Clin Oncol
; 148(11): 2985-2994, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34825950
4.
Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.
Diagnostics (Basel)
; 12(2)2022 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35204513
5.
Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study.
Front Oncol
; 11: 630136, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33833990
6.
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
J Clin Med
; 9(5)2020 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32384677
7.
Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients.
Med Oncol
; 37(12): 111, 2020 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33175248
8.
Osimertinib in first line setting: for Asian patients.
Transl Lung Cancer Res
; 8(4): 550-552, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31555530
Resultados
1 -
8
de 8
1
Próxima >
>>